Home›Research›Compare›CGRP vs TB-500
Peptide ComparisonCGRP vs TB-500
Both are Tissue Repair peptides.
CGRP
Calcitonin Gene-Related Peptide
Half-life: ~3.6 min / ~13.6 min (biphasic; sheep)
2 providers listed
TB-500
TB-500 (TB4)
Half-life: 5–7 days
406 providers listed
CGRP carries stronger published evidence (RCT, 10 key studies) than TB-500 (Review, 3); both are research compounds.
CGRP
Half-life
~3.6 min / ~13.6 min (biphasic; sheep)
TB-500
Half-life
5–7 days
| Your goal | Better option |
|---|---|
| Stronger clinical evidence | CGRP |
| Less frequent dosing (longer half-life) | TB-500 |
| More provider options (2 vs 406) | TB-500 |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
CGRP
TB-500
CGRP
Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous prevent…
A Controlled Trial of Erenumab for Episodic Migraine
Three-year real-world effectiveness, treatment persistence, and planned discontinuation of anti-calcitonin ge…
Functional role of Nav1.8 channels in action potentials of mouse CGRP-lineage dorsal root ganglion neurons.
+6 more
TB-500
Thymosin β4 and its degradation product, Ac-SDKP, are novel reparative factors in renal fibrosis
Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db…
Tβ4-Ac-SDKP pathway: Any relevance for the cardiovascular system?
About CGRP
Binds CLR/RAMP1 receptor complex. Causes vasodilation via cAMP/PKA/nitric oxide pathway. Modulates nociceptive signaling in the trigeminal system. Promotes bone healing and has anti-inflammatory effects in peripheral tissues.
About TB-500
TB-500 exerts its effects primarily through promotion of actin polymerisation and cell migration. It upregulates the expression of beta-4 thymosin, which facilitates endothelial and muscle satellite cell movement to injury sites. Unlike BPC-157, TB-500 appears to act via a more systemic mechanism rather than locally at the administration site.
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
CGRP
No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.
Under clinical review
Being verified by our medical team before we display monitoring guidance for this peptide.
TB-500
Under clinical review
Being verified by our medical team before we display contraindications for this peptide.
global — WADA
TB-500 / thymosin β4 is on the WADA Prohibited List at all times (S2.3, Growth Factors), effective 2018. It has no FDA approval and no human RCT evidence for injectable use.
sourceTB-500
BPC-157
Research suggests BPC-157 and TB-500 may produce enhanced tissue repair effects when combined. BPC-157 is studied for angiogenesis and gut-protective properties, while TB-500 promotes actin assembly and cell migration — complementary mechanisms in healing models.
CGRP
Not enough vendor pricing yet.
TB-500
Where to source these peptides
CGRP
2 listed
Browse directory →
Providers offeringTB-500
406 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More Tissue Repair Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated August 26, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). CGRP vs TB-500 — Per-mg Price Comparison. Retrieved September 11, 2026, from https://peptidebase.io/peptides/compare/cgrp/tb-500